Analysis of antifungal resistance genes in Candida albicans and Candida glabrata using next generation sequencing

PLoS One. 2019 Jan 10;14(1):e0210397. doi: 10.1371/journal.pone.0210397. eCollection 2019.

Abstract

Introduction/objectives: An increase in antifungal resistant Candida strains has been reported in recent years. The aim of this study was to detect mutations in resistance genes of azole-resistant, echinocandin-resistant or multi-resistant strains using next generation sequencing technology, which allows the analysis of multiple resistance mechanisms in a high throughput setting.

Methods: Forty clinical Candida isolates (16 C. albicans and 24 C. glabrata strains) with MICs for azoles and echinocandins above the clinical EUCAST breakpoint were examined. The genes ERG11, ERG3, TAC1 and GSC1 (FKS1) in C. albicans, as well as ERG11, CgPDR1, FKS1 and FKS2 in C. glabrata were sequenced.

Results: Fifty-four different missense mutations were identified, 13 of which have not been reported before. All nine echinocandin-resistant Candida isolates showed mutations in the hot spot (HS) regions of FKS1, FKS2 or GSC1. In ERG3 two homozygous premature stop codons were identified in two highly azole-resistant and moderately echinocandin-resistant C. albicans strains. Seven point mutations in ERG11 were determined in azole-resistant C. albicans whereas in azole-resistant C. glabrata, no ERG11 mutations were detected. In 10 out of 13 azole-resistant C. glabrata, 12 different potential gain-of-function mutations in the transcription factor CgPDR1 were verified, which are associated with an overexpression of the efflux pumps CDR1/2.

Conclusion: This study showed that next generation sequencing allows the thorough investigation of a large number of isolates more cost efficient and faster than conventional Sanger sequencing. Targeting different resistance genes and a large sample size of highly resistant strains allows a better determination of the relevance of the different mutations, and to differentiate between causal mutations and polymorphisms.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antifungal Agents / pharmacology
  • Candida albicans / drug effects
  • Candida albicans / genetics*
  • Candida glabrata / drug effects
  • Candida glabrata / genetics*
  • Computational Biology
  • Drug Resistance, Fungal / genetics*
  • Microbial Sensitivity Tests
  • Mutation
  • Sequence Analysis, DNA

Substances

  • Antifungal Agents

Grants and funding

This work was supported by a grant from Pfizer Austria. The funder had no role in study design, data analysis and preparation of the manuscript and in the decision to publish. Pure substance of micafungin was provided by Astellas GmbH, Austria. BW has received a grant by Pfizer and served on the speaker’s bureau of Pfizer, Merck Sharpe & Dohme, Basilea, Gilead and Astellas.